IBDEI00N ; ; 01-AUG-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1004,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1004,1,3,0)
 ;;=3^Hodgkin lymphoma, unspecified, unspecified site
 ;;^UTILITY(U,$J,358.3,1004,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,1004,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,1005,0)
 ;;=C82.69^^10^74^17
 ;;^UTILITY(U,$J,358.3,1005,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1005,1,3,0)
 ;;=3^Cutan folicl center lymphoma, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,1005,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,1005,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,1006,0)
 ;;=C82.60^^10^74^18
 ;;^UTILITY(U,$J,358.3,1006,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1006,1,3,0)
 ;;=3^Cutaneous follicle center lymphoma, unspecified site
 ;;^UTILITY(U,$J,358.3,1006,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,1006,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,1007,0)
 ;;=C82.49^^10^74^33
 ;;^UTILITY(U,$J,358.3,1007,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1007,1,3,0)
 ;;=3^Follicular lymphoma grade IIIb, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,1007,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,1007,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,1008,0)
 ;;=C82.40^^10^74^34
 ;;^UTILITY(U,$J,358.3,1008,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1008,1,3,0)
 ;;=3^Follicular lymphoma grade IIIb, unspecified site
 ;;^UTILITY(U,$J,358.3,1008,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,1008,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,1009,0)
 ;;=C82.19^^10^74^28
 ;;^UTILITY(U,$J,358.3,1009,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1009,1,3,0)
 ;;=3^Follicular lymphoma grade II, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,1009,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,1009,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,1010,0)
 ;;=C82.39^^10^74^31
 ;;^UTILITY(U,$J,358.3,1010,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1010,1,3,0)
 ;;=3^Follicular lymphoma grade IIIa, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,1010,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,1010,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,1011,0)
 ;;=C82.30^^10^74^32
 ;;^UTILITY(U,$J,358.3,1011,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1011,1,3,0)
 ;;=3^Follicular lymphoma grade IIIa, unspecified site
 ;;^UTILITY(U,$J,358.3,1011,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,1011,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,1012,0)
 ;;=C82.29^^10^74^25
 ;;^UTILITY(U,$J,358.3,1012,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1012,1,3,0)
 ;;=3^Follicular lymph grade III, unsp, extrnod and solid org sites
 ;;^UTILITY(U,$J,358.3,1012,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,1012,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,1013,0)
 ;;=C82.20^^10^74^30
 ;;^UTILITY(U,$J,358.3,1013,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1013,1,3,0)
 ;;=3^Follicular lymphoma grade III, unspecified, unspecified site
 ;;^UTILITY(U,$J,358.3,1013,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,1013,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,1014,0)
 ;;=C82.09^^10^74^26
 ;;^UTILITY(U,$J,358.3,1014,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1014,1,3,0)
 ;;=3^Follicular lymphoma grade I, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,1014,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,1014,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,1015,0)
 ;;=C82.10^^10^74^29
 ;;^UTILITY(U,$J,358.3,1015,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1015,1,3,0)
 ;;=3^Follicular lymphoma grade II, unspecified site
 ;;^UTILITY(U,$J,358.3,1015,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,1015,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,1016,0)
 ;;=C82.00^^10^74^27
 ;;^UTILITY(U,$J,358.3,1016,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1016,1,3,0)
 ;;=3^Follicular lymphoma grade I, unspecified site
 ;;^UTILITY(U,$J,358.3,1016,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,1016,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,1017,0)
 ;;=C82.90^^10^74^36
 ;;^UTILITY(U,$J,358.3,1017,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1017,1,3,0)
 ;;=3^Follicular lymphoma, unspecified, unspecified site
 ;;^UTILITY(U,$J,358.3,1017,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,1017,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,1018,0)
 ;;=C82.99^^10^74^35
 ;;^UTILITY(U,$J,358.3,1018,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1018,1,3,0)
 ;;=3^Follicular lymphoma, unsp, extranodal and solid organ sites
 ;;^UTILITY(U,$J,358.3,1018,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,1018,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,1019,0)
 ;;=C84.00^^10^74^60
 ;;^UTILITY(U,$J,358.3,1019,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1019,1,3,0)
 ;;=3^Mycosis fungoides, unspecified site
 ;;^UTILITY(U,$J,358.3,1019,1,4,0)
 ;;=4^C84.00
 ;;^UTILITY(U,$J,358.3,1019,2)
 ;;=^5001621
 ;;^UTILITY(U,$J,358.3,1020,0)
 ;;=C84.09^^10^74^59
 ;;^UTILITY(U,$J,358.3,1020,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1020,1,3,0)
 ;;=3^Mycosis fungoides, extranodal and solid organ sites
 ;;^UTILITY(U,$J,358.3,1020,1,4,0)
 ;;=4^C84.09
 ;;^UTILITY(U,$J,358.3,1020,2)
 ;;=^5001630
 ;;^UTILITY(U,$J,358.3,1021,0)
 ;;=C84.60^^10^74^8
 ;;^UTILITY(U,$J,358.3,1021,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1021,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-positive, unsp site
 ;;^UTILITY(U,$J,358.3,1021,1,4,0)
 ;;=4^C84.60
 ;;^UTILITY(U,$J,358.3,1021,2)
 ;;=^5001651
 ;;^UTILITY(U,$J,358.3,1022,0)
 ;;=C84.69^^10^74^10
 ;;^UTILITY(U,$J,358.3,1022,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1022,1,3,0)
 ;;=3^Anaplstc lg cell lymph, ALK-pos, extrnod and solid org sites
 ;;^UTILITY(U,$J,358.3,1022,1,4,0)
 ;;=4^C84.69
 ;;^UTILITY(U,$J,358.3,1022,2)
 ;;=^5001660
 ;;^UTILITY(U,$J,358.3,1023,0)
 ;;=C84.70^^10^74^7
 ;;^UTILITY(U,$J,358.3,1023,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1023,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-negative, unsp site
 ;;^UTILITY(U,$J,358.3,1023,1,4,0)
 ;;=4^C84.70
 ;;^UTILITY(U,$J,358.3,1023,2)
 ;;=^5001661
 ;;^UTILITY(U,$J,358.3,1024,0)
 ;;=C84.79^^10^74^9
 ;;^UTILITY(U,$J,358.3,1024,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1024,1,3,0)
 ;;=3^Anaplstc lg cell lymph, ALK-neg, extrnod and solid org sites
 ;;^UTILITY(U,$J,358.3,1024,1,4,0)
 ;;=4^C84.79
 ;;^UTILITY(U,$J,358.3,1024,2)
 ;;=^5001670
 ;;^UTILITY(U,$J,358.3,1025,0)
 ;;=C91.40^^10^74^37
 ;;^UTILITY(U,$J,358.3,1025,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1025,1,3,0)
 ;;=3^Hairy cell leukemia not having achieved remission
 ;;^UTILITY(U,$J,358.3,1025,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,1025,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,1026,0)
 ;;=C91.41^^10^74^39
 ;;^UTILITY(U,$J,358.3,1026,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1026,1,3,0)
 ;;=3^Hairy cell leukemia, in remission
 ;;^UTILITY(U,$J,358.3,1026,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,1026,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,1027,0)
 ;;=C91.42^^10^74^38
 ;;^UTILITY(U,$J,358.3,1027,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1027,1,3,0)
 ;;=3^Hairy cell leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,1027,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,1027,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,1028,0)
 ;;=C96.4^^10^74^71
 ;;^UTILITY(U,$J,358.3,1028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1028,1,3,0)
 ;;=3^Sarcoma of dendritic cells (accessory cells)
 ;;^UTILITY(U,$J,358.3,1028,1,4,0)
 ;;=4^C96.4
 ;;^UTILITY(U,$J,358.3,1028,2)
 ;;=^5001861
 ;;^UTILITY(U,$J,358.3,1029,0)
 ;;=C96.9^^10^74^50
 ;;^UTILITY(U,$J,358.3,1029,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1029,1,3,0)
 ;;=3^Malig neoplm of lymphoid, hematpoetc and rel tissue, unsp
 ;;^UTILITY(U,$J,358.3,1029,1,4,0)
 ;;=4^C96.9
 ;;^UTILITY(U,$J,358.3,1029,2)
 ;;=^5001864
 ;;^UTILITY(U,$J,358.3,1030,0)
 ;;=C90.00^^10^74^58
 ;;^UTILITY(U,$J,358.3,1030,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1030,1,3,0)
 ;;=3^Multiple myeloma not having achieved remission
 ;;^UTILITY(U,$J,358.3,1030,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,1030,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,1031,0)
 ;;=C90.01^^10^74^57
 ;;^UTILITY(U,$J,358.3,1031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1031,1,3,0)
 ;;=3^Multiple myeloma in remission
 ;;^UTILITY(U,$J,358.3,1031,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,1031,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,1032,0)
 ;;=C90.02^^10^74^56
 ;;^UTILITY(U,$J,358.3,1032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1032,1,3,0)
 ;;=3^Multiple myeloma in relapse
 ;;^UTILITY(U,$J,358.3,1032,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,1032,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,1033,0)
 ;;=C91.00^^10^74^1
 ;;^UTILITY(U,$J,358.3,1033,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1033,1,3,0)
 ;;=3^Acute lymphoblastic leukemia not having achieved remission
 ;;^UTILITY(U,$J,358.3,1033,1,4,0)
 ;;=4^C91.00
 ;;^UTILITY(U,$J,358.3,1033,2)
 ;;=^5001762
 ;;^UTILITY(U,$J,358.3,1034,0)
 ;;=C91.01^^10^74^3
 ;;^UTILITY(U,$J,358.3,1034,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1034,1,3,0)
 ;;=3^Acute lymphoblastic leukemia, in remission
 ;;^UTILITY(U,$J,358.3,1034,1,4,0)
 ;;=4^C91.01
 ;;^UTILITY(U,$J,358.3,1034,2)
 ;;=^5001763
 ;;^UTILITY(U,$J,358.3,1035,0)
 ;;=C91.02^^10^74^2
 ;;^UTILITY(U,$J,358.3,1035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1035,1,3,0)
 ;;=3^Acute lymphoblastic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,1035,1,4,0)
 ;;=4^C91.02
 ;;^UTILITY(U,$J,358.3,1035,2)
 ;;=^5001764
 ;;^UTILITY(U,$J,358.3,1036,0)
 ;;=C91.10^^10^74^13
 ;;^UTILITY(U,$J,358.3,1036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1036,1,3,0)
 ;;=3^Chronic lymphocytic leuk of B-cell type not achieve remis
 ;;^UTILITY(U,$J,358.3,1036,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,1036,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,1037,0)
 ;;=C91.11^^10^74^14
 ;;^UTILITY(U,$J,358.3,1037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1037,1,3,0)
 ;;=3^Chronic lymphocytic leukemia of B-cell type in remission
 ;;^UTILITY(U,$J,358.3,1037,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,1037,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,1038,0)
 ;;=C91.12^^10^74^15
 ;;^UTILITY(U,$J,358.3,1038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1038,1,3,0)
 ;;=3^Chronic lymphocytic leukemia of B-cell type in relapse
 ;;^UTILITY(U,$J,358.3,1038,1,4,0)
 ;;=4^C91.12
 ;;^UTILITY(U,$J,358.3,1038,2)
 ;;=^5001767
 ;;^UTILITY(U,$J,358.3,1039,0)
 ;;=D47.1^^10^74^16
 ;;^UTILITY(U,$J,358.3,1039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1039,1,3,0)
 ;;=3^Chronic myeloproliferative disease
 ;;^UTILITY(U,$J,358.3,1039,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,1039,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,1040,0)
 ;;=C94.42^^10^74^5
 ;;^UTILITY(U,$J,358.3,1040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1040,1,3,0)
 ;;=3^Acute panmyelosis with myelofibrosis, in relapse
 ;;^UTILITY(U,$J,358.3,1040,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,1040,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,1041,0)
 ;;=C94.41^^10^74^6
 ;;^UTILITY(U,$J,358.3,1041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1041,1,3,0)
 ;;=3^Acute panmyelosis with myelofibrosis, in remission
 ;;^UTILITY(U,$J,358.3,1041,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,1041,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,1042,0)
 ;;=C94.40^^10^74^4
 ;;^UTILITY(U,$J,358.3,1042,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1042,1,3,0)
 ;;=3^Acute panmyelosis w myelofibrosis not achieve remission
 ;;^UTILITY(U,$J,358.3,1042,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,1042,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,1043,0)
 ;;=D47.2^^10^74^55
 ;;^UTILITY(U,$J,358.3,1043,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1043,1,3,0)
 ;;=3^Monoclonal gammopathy
 ;;^UTILITY(U,$J,358.3,1043,1,4,0)
 ;;=4^D47.2
 ;;^UTILITY(U,$J,358.3,1043,2)
 ;;=^5002257
 ;;^UTILITY(U,$J,358.3,1044,0)
 ;;=C88.0^^10^74^76
 ;;^UTILITY(U,$J,358.3,1044,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1044,1,3,0)
 ;;=3^Waldenstrom macroglobulinemia
 ;;^UTILITY(U,$J,358.3,1044,1,4,0)
 ;;=4^C88.0
 ;;^UTILITY(U,$J,358.3,1044,2)
 ;;=^5001748
 ;;^UTILITY(U,$J,358.3,1045,0)
 ;;=C81.70^^10^74^41
 ;;^UTILITY(U,$J,358.3,1045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1045,1,3,0)
 ;;=3^Hodgkin Lymphoma,Classical,Unspec Site NEC
 ;;^UTILITY(U,$J,358.3,1045,1,4,0)
 ;;=4^C81.70
 ;;^UTILITY(U,$J,358.3,1045,2)
 ;;=^5001441
 ;;^UTILITY(U,$J,358.3,1046,0)
 ;;=C81.79^^10^74^40
 ;;^UTILITY(U,$J,358.3,1046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1046,1,3,0)
 ;;=3^Hodgkin Lymphoma,Classical,Extrnod/Solid Organ Sites NEC
 ;;^UTILITY(U,$J,358.3,1046,1,4,0)
 ;;=4^C81.79
 ;;^UTILITY(U,$J,358.3,1046,2)
 ;;=^5001450
 ;;^UTILITY(U,$J,358.3,1047,0)
 ;;=C82.50^^10^74^20
 ;;^UTILITY(U,$J,358.3,1047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1047,1,3,0)
 ;;=3^Diffuse Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,1047,1,4,0)
 ;;=4^C82.50
 ;;^UTILITY(U,$J,358.3,1047,2)
 ;;=^5001511
 ;;^UTILITY(U,$J,358.3,1048,0)
 ;;=C82.59^^10^74^19
 ;;^UTILITY(U,$J,358.3,1048,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1048,1,3,0)
 ;;=3^Diffuse Follicle Center Lymphoma,Extrnod/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,1048,1,4,0)
 ;;=4^C82.59
 ;;^UTILITY(U,$J,358.3,1048,2)
 ;;=^5001520
 ;;^UTILITY(U,$J,358.3,1049,0)
 ;;=C82.80^^10^74^24
 ;;^UTILITY(U,$J,358.3,1049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1049,1,3,0)
 ;;=3^Follicular Lymphoma,Unspec Site NEC
 ;;^UTILITY(U,$J,358.3,1049,1,4,0)
 ;;=4^C82.80
 ;;^UTILITY(U,$J,358.3,1049,2)
 ;;=^5001531
 ;;^UTILITY(U,$J,358.3,1050,0)
 ;;=C82.89^^10^74^23
 ;;^UTILITY(U,$J,358.3,1050,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1050,1,3,0)
 ;;=3^Follicular Lymphoma,Extrnod/Solid Organ Sites NEC
 ;;^UTILITY(U,$J,358.3,1050,1,4,0)
 ;;=4^C82.89
 ;;^UTILITY(U,$J,358.3,1050,2)
 ;;=^5001540
 ;;^UTILITY(U,$J,358.3,1051,0)
 ;;=C83.00^^10^74^75
 ;;^UTILITY(U,$J,358.3,1051,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1051,1,3,0)
 ;;=3^Small Cell B-Cell Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,1051,1,4,0)
 ;;=4^C83.00
 ;;^UTILITY(U,$J,358.3,1051,2)
 ;;=^5001551
 ;;^UTILITY(U,$J,358.3,1052,0)
 ;;=C83.09^^10^74^74
 ;;^UTILITY(U,$J,358.3,1052,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1052,1,3,0)
 ;;=3^Small Cell B-Cell Lymphoma,Extrnod/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,1052,1,4,0)
 ;;=4^C83.09
 ;;^UTILITY(U,$J,358.3,1052,2)
 ;;=^5001560
 ;;^UTILITY(U,$J,358.3,1053,0)
 ;;=C83.30^^10^74^21
 ;;^UTILITY(U,$J,358.3,1053,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1053,1,3,0)
 ;;=3^Diffuse Large B-Cell Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,1053,1,4,0)
 ;;=4^C83.30
 ;;^UTILITY(U,$J,358.3,1053,2)
 ;;=^5001571
 ;;^UTILITY(U,$J,358.3,1054,0)
 ;;=C83.80^^10^74^66
 ;;^UTILITY(U,$J,358.3,1054,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1054,1,3,0)
 ;;=3^Non-Follicular Lymphoma,Unspec Site NEC
 ;;^UTILITY(U,$J,358.3,1054,1,4,0)
 ;;=4^C83.80
 ;;^UTILITY(U,$J,358.3,1054,2)
 ;;=^5001601
 ;;^UTILITY(U,$J,358.3,1055,0)
 ;;=C83.89^^10^74^65
 ;;^UTILITY(U,$J,358.3,1055,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1055,1,3,0)
 ;;=3^Non-Follicular Lymphoma,Extrnod/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,1055,1,4,0)
 ;;=4^C83.89
 ;;^UTILITY(U,$J,358.3,1055,2)
 ;;=^5001610
 ;;^UTILITY(U,$J,358.3,1056,0)
 ;;=C83.90^^10^74^68
 ;;^UTILITY(U,$J,358.3,1056,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1056,1,3,0)
 ;;=3^Non-Follicular Lymphoma,Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,1056,1,4,0)
 ;;=4^C83.90
 ;;^UTILITY(U,$J,358.3,1056,2)
 ;;=^5001611
 ;;^UTILITY(U,$J,358.3,1057,0)
 ;;=C83.99^^10^74^67
 ;;^UTILITY(U,$J,358.3,1057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1057,1,3,0)
 ;;=3^Non-Follicular Lymphoma,Unspec,Extranod/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,1057,1,4,0)
 ;;=4^C83.99
 ;;^UTILITY(U,$J,358.3,1057,2)
 ;;=^5001620
 ;;^UTILITY(U,$J,358.3,1058,0)
 ;;=C84.10^^10^74^73
 ;;^UTILITY(U,$J,358.3,1058,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1058,1,3,0)
 ;;=3^Sezary Disease,Unspec Site
 ;;^UTILITY(U,$J,358.3,1058,1,4,0)
 ;;=4^C84.10
 ;;^UTILITY(U,$J,358.3,1058,2)
 ;;=^5001631
 ;;^UTILITY(U,$J,358.3,1059,0)
 ;;=C84.19^^10^74^72
 ;;^UTILITY(U,$J,358.3,1059,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1059,1,3,0)
 ;;=3^Sezary Disease,Extrnod/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,1059,1,4,0)
 ;;=4^C84.19
 ;;^UTILITY(U,$J,358.3,1059,2)
 ;;=^5001640
 ;;^UTILITY(U,$J,358.3,1060,0)
 ;;=C84.40^^10^74^70
 ;;^UTILITY(U,$J,358.3,1060,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1060,1,3,0)
 ;;=3^Peripheral T-Cell Lymphoma,Unspec Site NEC
 ;;^UTILITY(U,$J,358.3,1060,1,4,0)
 ;;=4^C84.40
 ;;^UTILITY(U,$J,358.3,1060,2)
 ;;=^5001641
 ;;^UTILITY(U,$J,358.3,1061,0)
 ;;=C84.49^^10^74^69
 ;;^UTILITY(U,$J,358.3,1061,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1061,1,3,0)
 ;;=3^Peripheral T-Cell Lymphoma,Extrnod/Solid Organ Sites NEC
 ;;^UTILITY(U,$J,358.3,1061,1,4,0)
 ;;=4^C84.49
 ;;^UTILITY(U,$J,358.3,1061,2)
 ;;=^5001650
 ;;^UTILITY(U,$J,358.3,1062,0)
 ;;=C77.0^^10^75^14
 ;;^UTILITY(U,$J,358.3,1062,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1062,1,3,0)
 ;;=3^Secondary malignant neoplasm of nodes of head, face and neck
 ;;^UTILITY(U,$J,358.3,1062,1,4,0)
 ;;=4^C77.0
 ;;^UTILITY(U,$J,358.3,1062,2)
 ;;=^5001329
 ;;^UTILITY(U,$J,358.3,1063,0)
 ;;=C77.1^^10^75^9
 ;;^UTILITY(U,$J,358.3,1063,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1063,1,3,0)
 ;;=3^Secondary malignant neoplasm of intrathorac nodes
 ;;^UTILITY(U,$J,358.3,1063,1,4,0)
 ;;=4^C77.1
 ;;^UTILITY(U,$J,358.3,1063,2)
 ;;=^267315
 ;;^UTILITY(U,$J,358.3,1064,0)
 ;;=C77.2^^10^75^7
 ;;^UTILITY(U,$J,358.3,1064,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1064,1,3,0)
 ;;=3^Secondary malignant neoplasm of intra-abd nodes
 ;;^UTILITY(U,$J,358.3,1064,1,4,0)
 ;;=4^C77.2
 ;;^UTILITY(U,$J,358.3,1064,2)
 ;;=^267316
 ;;^UTILITY(U,$J,358.3,1065,0)
 ;;=C77.3^^10^75^1
 ;;^UTILITY(U,$J,358.3,1065,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1065,1,3,0)
 ;;=3^Secondary malignant neoplasm of axilla and upper limb nodes
 ;;^UTILITY(U,$J,358.3,1065,1,4,0)
 ;;=4^C77.3
 ;;^UTILITY(U,$J,358.3,1065,2)
 ;;=^5001330
 ;;^UTILITY(U,$J,358.3,1066,0)
 ;;=C77.4^^10^75^6
 ;;^UTILITY(U,$J,358.3,1066,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1066,1,3,0)
 ;;=3^Secondary malignant neoplasm of inguinal and lower limb nodes
 ;;^UTILITY(U,$J,358.3,1066,1,4,0)
 ;;=4^C77.4
 ;;^UTILITY(U,$J,358.3,1066,2)
 ;;=^5001331
 ;;^UTILITY(U,$J,358.3,1067,0)
 ;;=C77.8^^10^75^15
 ;;^UTILITY(U,$J,358.3,1067,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1067,1,3,0)
 ;;=3^Secondary malignant neoplasm of nodes of multiple regions
 ;;^UTILITY(U,$J,358.3,1067,1,4,0)
 ;;=4^C77.8
 ;;^UTILITY(U,$J,358.3,1067,2)
 ;;=^5001332
 ;;^UTILITY(U,$J,358.3,1068,0)
 ;;=C77.9^^10^75^13
 ;;^UTILITY(U,$J,358.3,1068,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1068,1,3,0)
 ;;=3^Secondary malignant neoplasm of lymph node, unsp
 ;;^UTILITY(U,$J,358.3,1068,1,4,0)
 ;;=4^C77.9
 ;;^UTILITY(U,$J,358.3,1068,2)
 ;;=^5001333
 ;;^UTILITY(U,$J,358.3,1069,0)
 ;;=C78.01^^10^75^18
 ;;^UTILITY(U,$J,358.3,1069,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1069,1,3,0)
 ;;=3^Secondary malignant neoplasm of right lung
 ;;^UTILITY(U,$J,358.3,1069,1,4,0)
 ;;=4^C78.01
 ;;^UTILITY(U,$J,358.3,1069,2)
 ;;=^5001335
 ;;^UTILITY(U,$J,358.3,1070,0)
 ;;=C78.02^^10^75^11
 ;;^UTILITY(U,$J,358.3,1070,1,0)
 ;;=^358.31IA^4^2
